Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)

International Journal of Cancer

Volumn 92, Issue 4, 2001, Pages 497-502

  Borgfeldt, Christer ^a   Hansson, Stefan R ^a   Gustavsson, Barbro ^a   Måsbäck, Anna ^a   Casslén, Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Human; mRNA analysis; Ovarian neoplasm; Plasminogen activation; Urokinase

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER GROWTH; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CELL MIGRATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; METASTASIS; OVARY CANCER; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

BLOTTING, NORTHERN; CELL DIFFERENTIATION; CELL DIVISION; DENSITOMETRY; FEMALE; FIBROBLASTS; HUMANS; IN SITU HYBRIDIZATION; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RNA, COMPLEMENTARY; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035874046     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1215     Document Type: Article

References (34)

1. The plasminogen activation system in tumor growth, invasion, and metastasis
2. Role of urokinase receptor and caveolin in regulation of integrin signaling
3. Integrin signaling: Cytoskeletal complexes, MAP kinase activation, and regulation of gene expression
4. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma
5. Proteases as prognostic markers in cancer
6. The urokinase-type plasminogen activator system in cancer metastasis: A review
7. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
8. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
9. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
10. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization
11. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo
12. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo
13. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas
14. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA
15. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
16. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor
17. In situ hybridization histochemistry
18. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
19. Overview - The genetics of ovarian cancer
20. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors
21. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer
22. Regulation of integrin function by the urokinase receptor
23. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling
24. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients
25. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
26. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma
27. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
28. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas
29. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization
30. Recycling of the urokinase receptor upon internalization of the uPA: Serpin complexes
31. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor
32. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
33. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
34. Human endothelial cell migration is stimulated by urokinase plasminogen activator: Plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor β1; possible mechanism for paracrine stimulation of endometrial angiogenesis